These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 29141790)

  • 1. Cerebral toxoplasmosis in an MS patient receiving Fingolimod.
    Enriquez-Marulanda A; Valderrama-Chaparro J; Parrado L; Diego Vélez J; Maria Granados A; Luis Orozco J; Quiñones J
    Mult Scler Relat Disord; 2017 Nov; 18():106-108. PubMed ID: 29141790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings.
    Chong I; Wang KY; Lincoln CM
    Clin Imaging; 2019; 54():53-56. PubMed ID: 30544079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod.
    Harrer A; Wipfler P; Pilz G; Oppermann K; Haschke-Becher E; Afazel S; Kraus J; Trinka E; Sellner J
    Int J Mol Sci; 2015 Sep; 16(9):21832-45. PubMed ID: 26378517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.
    Baharnoori M; Gonzalez CT; Chua A; Diaz-Cruz C; Healy BC; Stankiewicz J; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2018 Feb; 20():51-57. PubMed ID: 29304497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging tumefactive MS after switching therapy from interferon-beta to fingolimod: A case report.
    Harirchian MH; Taalimi A; Siroos B
    Mult Scler Relat Disord; 2015 Sep; 4(5):400-402. PubMed ID: 26346786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of dosage reduction on peripheral blood lymphocyte count in patients with multiple sclerosis receiving long-term fingolimod therapy.
    Takahashi K
    J Clin Neurosci; 2019 May; 63():91-94. PubMed ID: 30772201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumefactive demyelinating lesions: A comprehensive review.
    Algahtani H; Shirah B; Alassiri A
    Mult Scler Relat Disord; 2017 May; 14():72-79. PubMed ID: 28619436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The frequency of varicella-zoster virus infection in patients with multiple sclerosis receiving fingolimod.
    Aramideh Khouy R; Karampoor S; Keyvani H; Bokharaei-Salim F; Monavari SH; Taghinezhad S; Etemadifar M; Esghaei M
    J Neuroimmunol; 2019 Mar; 328():94-97. PubMed ID: 30610966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
    Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS
    JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections?
    Carpenter AF; Goodwin SJ; Bornstein PF; Larson AJ; Markus CK
    Mult Scler; 2017 Feb; 23(2):297-299. PubMed ID: 28165320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events.
    Fragoso YD
    Acta Neurol Belg; 2017 Dec; 117(4):821-827. PubMed ID: 28528469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis.
    Ward MD; Jones DE; Goldman MD
    Mult Scler Relat Disord; 2016 Sep; 9():47-9. PubMed ID: 27645342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fingolimod-induced leukoencephalopathy in a patient with neuromyelitis optica spectrum disorder.
    Yoshii F; Moriya Y; Ohnuki T; Ryo M; Takahashi W
    Mult Scler Relat Disord; 2016 May; 7():53-7. PubMed ID: 27237757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe aseptic temporal lobe encephalitis on fingolimod.
    Rotstein DL; Bharatha A; Selchen D
    Mult Scler Relat Disord; 2018 Jul; 23():4-6. PubMed ID: 29689473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The risk of varicella zoster virus infection in multiple sclerosis patients treated with fingolimod].
    Tanaka M
    Rinsho Shinkeigaku; 2016 Apr; 56(4):270-2. PubMed ID: 27010095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population.
    Boffa G; Bruschi N; Cellerino M; Lapucci C; Novi G; Sbragia E; Capello E; Uccelli A; Inglese M
    CNS Drugs; 2020 Apr; 34(4):425-432. PubMed ID: 32193826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis.
    Tagawa A; Ogawa T; Tetsuka S; Otsuka M; Hashimoto R; Kato H; Ando K; Tanabe H
    Mult Scler Relat Disord; 2016 Sep; 9():155-7. PubMed ID: 27645365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Listeria monocytogenes rhombencephalitis in a patient with multiple sclerosis during fingolimod therapy.
    Tecellioglu M; Kamisli O; Kamisli S; Erdogmus UA; Özcan C
    Mult Scler Relat Disord; 2019 Jan; 27():409-411. PubMed ID: 30530070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe rebound after withdrawal of fingolimod treatment in patients with multiple sclerosis.
    Gündüz T; Kürtüncü M; Eraksoy M
    Mult Scler Relat Disord; 2017 Jan; 11():1-3. PubMed ID: 28104247
    [No Abstract]   [Full Text] [Related]  

  • 20. Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS).
    Meissner A; Limmroth V
    Mult Scler Relat Disord; 2016 Jul; 8():19-26. PubMed ID: 27456870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.